Logo
x

Search

Subscribe Now

 EMA

Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

  • October 30, 2024
New Drug Designations - September 2024

New Drug Designations - September 2024

  • October 29, 2024
Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU

Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU

  • October 28, 2024
Alnylam Reports the Submission of Regulatory Application of Amvuttra (Vutrisiran) to the EMA Treating ATTR Amyloidosis with Cardiomyopathy

Alnylam Reports the Submission of Regulatory Application of Amvuttra (Vutrisiran) to the EMA Treating ATTR Amyloidosis with Cardio...

  • October 17, 2024
Merck Animal Health Reports the EMA’s Approval of an Expanded Indication for SC Administration of Bovilis Rotavec Corona

Merck Animal Health Reports the EMA’s Approval of an Expanded Indication for SC Administration of Bovilis Rotavec Corona

  • October 16, 2024
Alvotech Reports the EMA’s Acceptance of MAA for AVT03 (Biosimilar, Prolia and Xgeva)

Alvotech Reports the EMA’s Acceptance of MAA for AVT03 (Biosimilar, Prolia and Xgeva)

  • October 10, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.